Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04945824 · ClinicalTrials.gov registry record · Early Phase 1
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
A Early Phase 1 study, sponsored by Ocular Therapeutix.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT04945824: Clinical Trial Early Phase 1 study, sponsored by Ocular Therapeutix.
NCT04945824 is a Early Phase 1 study that was terminated before completion, run by Ocular Therapeutix. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04945824, a Early Phase 1 study, was terminated before completion, sponsored by Ocular Therapeutix.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximately 1 month from the DEXTENZA insertion.
Interventions
- DRUG Dexamethasone Ophthalmic
- DEVICE Dilator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2022-11-01 |
| Phase | Early Phase 1 |
Why NCT04945824 stopped before completion
NCT04945824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Ophthalmic is the first listed.
NCT04945824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04945824 about?
NCT04945824 is a clinical study titled "A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects". This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximat...
What is the current status of trial NCT04945824?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-06-01. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04945824?
The interventions under investigation include: Dexamethasone Ophthalmic (DRUG), Dilator (DEVICE).
Who is sponsoring clinical trial NCT04945824?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04945824's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI